Please login to the form below

Not currently logged in
Email:
Password:

Storm Therapeutics strengthens its board

Professor Paul Workman joins as an independent director

Paul WorkmanDrug discovery group Storm Therapeutics has appointed Professor Paul Workman to join its board.

He said: “I am delighted to be joining the board of Storm and working with the company in this exploding area of biology.

“RNA epigenetic modulation is an exciting area of science with real potential to deliver new targeted cancer therapies.

“I look forward to working with the board to help guide Storm’s innovative research programmes, adding my experience from drug discovery in academia, pharma and biotech.”

Workman currently serves The Institute of Cancer Research as its president and chief executive officer and has formerly served as head of the division of cancer therapeutics at Cancer Research UK.

Keith Blundy, CEO, Storm Therapeutics, said: “I am pleased to welcome Paul as indepdent director to Storm’s board.

“Paul brings a wealth of experience in cancer biology and drug discovery, in addition to the translational expertise of moving emerging biology to therapeutic applications through his experience of leading a world class cancer institute and being a founder of companies such as Piramed.

“We look forward to Paul’s input on development and positioning of Storm’s emerging RNA epigenetics platform and programmes.”

14th November 2017

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...